Compare Stocks: SEOVF, BPMX, BDTX, and GNLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$1.90 -4.0%	$1.98	$1.60 ▼ $4.94	$113.76M	3.31	562,138 shs	613,500 shs
BPMX Biopharmx		$0.00	$0.25 ▼ $6.30	$111.86M	N/A	2.15 million shs	336,508 shs
GNLX Genelux	$2.52 -3.4%	$2.69	$2.29 ▼ $8.53	$118.09M	0.57	298,304 shs	115,792 shs
SEOVF Sernova Biotherapeutics	$0.07 -2.1%	$0.08	$0.07 ▼ $0.15	$27M	0.86	163,702 shs	14,000 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	-4.04%	-2.06%	-11.63%	+11.76%	-40.06%
BPMX Biopharmx	0.00%	0.00%	0.00%	0.00%	0.00%
GNLX Genelux	-3.45%	+7.69%	-7.35%	-13.10%	-41.94%
SEOVF Sernova Biotherapeutics	-2.10%	-7.28%	-13.26%	-29.65%	-46.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$1.90 -4.0%	$1.98	$1.60 ▼ $4.94	$113.76M	3.31	562,138 shs	613,500 shs
BPMX Biopharmx		$0.00	$0.25 ▼ $6.30	$111.86M	N/A	2.15 million shs	336,508 shs
GNLX Genelux	$2.52 -3.4%	$2.69	$2.29 ▼ $8.53	$118.09M	0.57	298,304 shs	115,792 shs
SEOVF Sernova Biotherapeutics	$0.07 -2.1%	$0.08	$0.07 ▼ $0.15	$27M	0.86	163,702 shs	14,000 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	-4.04%	-2.06%	-11.63%	+11.76%	-40.06%
BPMX Biopharmx	0.00%	0.00%	0.00%	0.00%	0.00%
GNLX Genelux	-3.45%	+7.69%	-7.35%	-13.10%	-41.94%
SEOVF Sernova Biotherapeutics	-2.10%	-7.28%	-13.26%	-29.65%	-46.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	2.64	Moderate Buy	$10.25	439.47% Upside
BPMX Biopharmx	0.00	N/A	N/A	N/A
GNLX Genelux	2.80	Moderate Buy	$18.00	614.29% Upside
SEOVF Sernova Biotherapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SEOVF, BPMX, BDTX, and GNLX Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/16/2026	GNLX Genelux	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	GNLX Genelux	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Speculative Buy
8/6/2026	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	BDTX Black Diamond Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	BDTX Black Diamond Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	GNLX Genelux	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	BDTX Black Diamond Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	N/A	N/A	$0.51 per share	3.76	$1.97 per share	N/A
BPMX Biopharmx	N/A	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	$10K	11,400.48	N/A	N/A	$0.30 per share	8.40
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	($0.05) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	$22.37M	-$0.75	N/A	N/A	N/A	N/A	-32.10%	-25.21%	11/5/2026 (Estimated)
BPMX Biopharmx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	-$32.15M	-$0.86	N/A	N/A	N/A	N/A	-205.85%	-138.79%	11/4/2026 (Estimated)
SEOVF Sernova Biotherapeutics	-$11.24M	-$0.04	N/A	N/A	N/A	N/A	N/A	-926.94%	N/A

Latest SEOVF, BPMX, BDTX, and GNLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2026	Q3 2026	SEOVF Sernova Biotherapeutics	-$0.0050	-$0.01	-$0.0050	-$0.01	N/A	N/A
8/13/2026	Q2 2026	GNLX Genelux	-$0.1967	-$0.21	-$0.0133	-$0.21	N/A	N/A
8/5/2026	Q2 2026	BDTX Black Diamond Therapeutics	-$0.1954	-$0.17	+$0.0254	-$0.17	$5.56 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
BPMX Biopharmx	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	7.28	7.28
BPMX Biopharmx	N/A	N/A	N/A
GNLX Genelux	N/A	2.39	2.39
SEOVF Sernova Biotherapeutics	N/A	0.14	0.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
BPMX Biopharmx	N/A
GNLX Genelux	37.33%
SEOVF Sernova Biotherapeutics	N/A

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	9.29%
BPMX Biopharmx	N/A
GNLX Genelux	7.50%
SEOVF Sernova Biotherapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	21	57.45 million	52.12 million	Optionable
BPMX Biopharmx	17	18.28 million	N/A	Not Optionable
GNLX Genelux	26	45.24 million	41.85 million	Not Optionable
SEOVF Sernova Biotherapeutics	N/A	377.64 million	N/A	Not Optionable

SEOVF, BPMX, BDTX, and GNLX Headlines

Recent News About These Companies

Sernova Biotherapeutics Inc SEOVF

May 14, 2026 | morningstar.comM

Sernova Biotherapeutics Announces Closing of Recently Approved Financings

April 23, 2026 | newsfilecorp.comN

Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders

April 9, 2026 | newsfilecorp.comN

Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing

March 24, 2026 | newsfilecorp.comN

Sernova Biotherapeutics: Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to ...

March 4, 2026 | finanznachrichten.de

Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval

March 4, 2026 | newsfilecorp.comN

Sernova Biotherapeutics Announces Warrant Amendments

February 20, 2026 | newsfilecorp.comN

Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts

November 13, 2025 | finance.yahoo.com

Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang

October 1, 2025 | newsfilecorp.comN

Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors

September 23, 2025 | thenewswire.comT

Sernova Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investor Conference

September 8, 2025 | thenewswire.comT

Sernova Biotherapeutics Announces Collaboration with Eledon ...

July 11, 2025 | morningstar.comM

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

July 9, 2025 | globenewswire.com

Sernova Biotherapeutics Taps CEO to Be Interim Chair

June 2, 2025 | marketwatch.com

Sernova Appoints Jonathan Rigby as Interim Chair

June 2, 2025 | globenewswire.com

Chair of Sernova Biotherapeutics Resigns

May 25, 2025 | globenewswire.com

Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes

May 22, 2025 | globenewswire.com

Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes

May 14, 2025 | globenewswire.com

Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans

April 17, 2025 | globenewswire.com

Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med

April 15, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEOVF, BPMX, BDTX, and GNLX Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$1.90 -0.08 (-4.04%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.92 +0.03 (+1.32%)

As of 06:43 AM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Biopharmx NYSEAMERICAN:BPMX

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.

Genelux NASDAQ:GNLX

$2.52 -0.09 (-3.45%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.52 0.00 (-0.20%)

As of 09/23/2026 07:30 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Sernova Biotherapeutics OTCMKTS:SEOVF

$0.07 0.00 (-2.10%)

As of 09/23/2026 11:05 AM Eastern

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SEOVF, BPMX, BDTX, and GNLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SEOVF, BPMX, BDTX, and GNLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SEOVF, BPMX, BDTX, and GNLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEOVF, BPMX, BDTX, and GNLX Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

Biopharmx NYSEAMERICAN:BPMX

Genelux NASDAQ:GNLX

Sernova Biotherapeutics OTCMKTS:SEOVF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SEOVF, BPMX, BDTX, and GNLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SEOVF, BPMX, BDTX, and GNLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SEOVF, BPMX, BDTX, and GNLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEOVF, BPMX, BDTX, and GNLX Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

Biopharmx NYSEAMERICAN:BPMX

Genelux NASDAQ:GNLX

Sernova Biotherapeutics OTCMKTS:SEOVF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools